Kinnate Biopharma Inc. Appoints Neha Krishnamohan as CFO and Executive Vice President, Corporate Development and Expands its Leadership Team with Key New Hires
07 juin 2021 08h00 HE
|
Kinnate Biopharma
Experienced leaders bring substantial clinical research, regulatory, and operational expertise in the biopharmaceutical industry to the Kinnate team SAN FRANCISCO and SAN DIEGO, June 07, 2021 ...
Kinnate Biopharma Inc. Presents Preclinical Data From its Lead RAF Inhibitor Candidate KIN-2787 at ASCO 2021
04 juin 2021 08h00 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. to Participate at the Goldman Sachs 42nd Annual Global Healthcare Conference
25 mai 2021 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Reports First Quarter 2021 Financial Results and Announces FDA Clearance of Investigational New Drug Application for KIN-2787
17 mai 2021 16h05 HE
|
Kinnate Biopharma
KIN-2787 is the company’s RAF inhibitor candidate for patients with mutant BRAF-driven solid tumors Planned initiation of Phase 1 clinical trial for KIN-2787 in mid-2021 Ended the quarter with cash...
Kinnate Biopharma Inc. Closes $35 Million Series A Financing to Establish a Chinese Joint Venture
13 mai 2021 16h02 HE
|
Kinnate Biopharma
Financing led by OrbiMed Asia Partners, with participation from OrbiMed Private Investments and Foresite CapitalThe joint venture will have exclusive license to develop and commercialize Kinnate’s...
Kinnate Biopharma Inc. Announces the Departure of Dr. Stephen Kaldor from its Board of Directors
30 avr. 2021 08h00 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, April 30, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. Reports Full Year 2020 Financial Results
29 mars 2021 16h05 HE
|
Kinnate Biopharma
Completed recent IPO, raising $276MM in gross proceeds to fund kinase inhibitors for genomically defined cancers Progress towards IND filing for KIN-2787, our RAF inhibitor candidate, in the...
Kinnate Biopharma Inc. Announces Its Addition to the Russell 2000® Index
19 mars 2021 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, March 19, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
11 févr. 2021 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...
Kinnate Biopharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
07 déc. 2020 16h05 HE
|
Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small...